Artificial intelligence is redesigning the limits of what is possible in the development of medicines. For decades, the pharmaceutical business model has been built in the delivery of human intelligence as a service. Cro, sites and sponsors study teams have been the backbone of this system, meticulously managing studies through complex, manual and highly inefficient workflows. As a result, studies take years to complete and slow down the introduction of new medicines for patients. But that was now giving way to the AIQ age.
What is AIQ?
AIQ, or artificial intelligence ratio, is a measure of how much of the operations of your organization increase or replace the AI. It is the labor relationship enabled for machines for the effort directed by Human Acrross of the clinical trial value chain. At this time, our industry is operating in an AIQ near zero. But I think that won the last lung.
Because? Because clinical research as we know it simply does not. The volume of tests is exploiting, the new modalities are entering the pipe and expectations for faster, cheaper and higher quality execution are increasing. The traditional play book to hire more people and expect them to work harder is not to cut it. The way to follow is to increase human capacity by changing the proportion of people to the clinical development.
We are entering the era of abundance in clinical trials
For the first time, we have the tools to climb tests as never before. The problem is no longer a scientific discovery. With technologies such as Alpafold and the design of medicines with AI, the bottleneck has changed to the execution of the test. Now we face a massive mismatch between the potential of the modern discovery of drugs and the operational capacity of the clinical research ecosystem.
In this new era of abundance, we won a single moon. We will talk about the thousands, or goal shots. I think we will execute more evidence, in more indications, with more precision. But we don’t have the workforce, time or economy to do so in the old way.
Aiq in action
Let’s be directly: the Cro, the sponsor and the average site are operating with an AIQ from zero. Yes, they may have adopted some tools such as a clinical and clinical system or a programming platform there, but the thesis is disconnected, incremental systems that are often a load as large for the user as a blessing. But they are not a strategy.
The answer is to integrate the “teammates” of the AI (also known as agents) in the services stack, from project management to data operations and monitoring. These systems work together with humans for automatic traditional manual workflows and, therefore, improve bandwidth in all site staff to allow patient oriented more time. The configuration and maintenance of the study, as well as other aspects of the broader execution of the study, can be reduced by up to 80%, while improving quality and speed in each step.
Far from replacing staff, as they are feared, IA teammates will support clinical research coordinators by rationalizing administrative load, improving quality adhesion and protocol, and allowing perfect multithaece among studies. A higher AIQ relationship allows small equipment to handle many more clinical research loads than would be possible.
AIQ implications
As noted, Raising aiq is not about replacing people. It’s about empowering them. This is what happens when companies begin to change their relationship:
- Efficiency gains -AI assumes repetitive tasks such as consultation resolution, document management and compliance monitoring, releasing human talent to focus on strategic decisions and the resolution of higher order problems.
- Scalability – Organizations with higher aiq can execute more evidence with the same staff. That means less general expenses and more shots on the door.
- Competitive advantage – Sponsors already require faster deadlines and cleaner data. The Cro and the higher AIQ sites will meet these expectations.
- New business models -In real time panels, predictive analysis and proactive quality control, all leading to greater transparency and quality, as well as a more agile business model. None of this is possible in Aiq Zero, but they are feasible on any beach, and even possible of the table stakes, as the AIQ of an organization increases.
Raising AIQ is a strategic imperative
I think this is not a linear transformation, nor is it optional. Organizations that raise their AIQ will now define the future of clinical research. Those who are not far behind.
Companies that increase their AIQ will gain capacity without hiring, will improve quality and reduce error rates, unlock ideas in real time for faster, better decisions and will become magnets for associations and capital investment. And most importantly, they will be the positions to lead in the era of abundance.
Of lunar shots to the impulse
The idea of betting a large drug at the same time (the “lunarshot” model) will become obsolete with the highest AIQ, since companies will no longer have to do that compensation. Opus Genetics is the perfect example. They can pursue multiple programs, iterate faster and get answers before. That is what the next generation of biotechnology companies will require.
Nor do they need to transmit 80% of the workflows to see the value. In our experience, the turning point begins around 20-25% automation. It was then that organizations begin to release the equipment capacity and improve consistency.
And that can be achieved now. Technology exists and urgency is real. The only thing left is the commitment to change.
Aiq is the future of clinical research
Aiq is not just about adopting a new technology. We are talking about a different fundamental way of thinking. A change in what is possible in clinical research and a new standard for execution.
The gap between those who raise their year and those who did not win is narrow but more similar to an abyss. I think that now is the time for organizations to consider what their future will be in the era of the human increase through AI teammates.
Photo: Lvcandy, Getty Images
Ram Yalamanchiliis, the CEO and co -founder of Tilda Research. He believes that the future of clinical research is through the increase with AI teammates, and that we are just beginning.
This publication appears through Medical influencers program. Anyone can publish their perspective on business and innovation in medical care in Medcity News through influential people of Medcy. Click here to find out how.